Author Correction: The conformation-selective PI3Kδ inhibitor roginolisib in patients with advanced or metastatic cancer, including metastatic uveal melanoma: first-in-human clinical trial
Nature · By Anna Maria Di Giacomo ·
Nature Communications, Published online: 13 November 2026; doi:10.1038/s41467-026-79579-2 Author Correction: The conformation-selective PI3Kδ inhibitor roginolisib in patients with advanced or metastatic cancer, including metastatic uveal melanoma: first-in-human clinical trial